Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare’s SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
Data from this Non-Invasive, Highly Effective Treatment Option for Non-Melanoma Skin Cancer Published in Journal of Drugs in Dermatology BOCA RATON, Fla., Feb. 12, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), announces the […]
Sensus Healthcare to Host Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call on February 14, 2019
BOCA RATON, Fla., Jan. 30, 2019 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, February 14, 2019 at 4:30 p.m. Eastern time to discuss the financial results […]
Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial Radio Therapy
SRT-100, a Low-energy X-ray Technology, Used at Site of Keloidectomy Treatment BOCA RATON, Fla., Dec. 6, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), announced today positive results of a multicenter case series of […]
Sensus Healthcare Installs First Groundbreaking SRT-100+ Superficial Radio Therapy System for Treating Keloid Scars
Dr. Kenrick Spence of Hillcrest Plastic Surgery in Orlando First to Offer System BOCA RATON, Fla., Nov. 29, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), has installed its first SRT-100+ system at Hillcrest […]
Sensus Healthcare Third Quarter Financial Results Feature Revenue Growth of 32%
Shipped 18 systems during the quarter including 15 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 1, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results […]
Sensus Healthcare to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 1, 2018
BOCA RATON, Fla., Oct. 22, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, November 1, 2018 at 4:30 p.m. Eastern time to discuss the financial results […]
Sensus Healthcare Brings Groundbreaking SRT-100 Vision System to Israel’s Largest Hospital for Skin Cancer and Keloid Treatment
SRT-100 Vision Coming to Patients at Sheba Medical Center Near Tel Aviv BOCA RATON, Fla., Oct. 17, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced that the Company has shipped its third […]
South Florida Business Journal Recognizes Sensus Healthcare’s Chief Technology Officer at 2018 Technology Awards
BOCA RATON, Fla., Oct. 16, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced that the South Florida Business Journal has recognized the Company’s Chief Technology Officer, Kal Fishman, as a finalist at […]
Sensus Healthcare, Inc. Announces Underwriters’ Exercise of Option
BOCA RATON, Fla., Sept. 21, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it has issued an additional 330,882 shares of its common stock pursuant to the exercise in full of the underwriters’ option received in connection with Sensus’ recently completed public offering of its common stock. After giving effect to the full […]
Sensus Healthcare, Inc. Announces Closing of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 17, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it completed a public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. All of the shares were offered by Sensus. The shares are listed on The […]
